Cetuximab (anti-EGFR)
CAS No. 205923-56-4
Cetuximab (anti-EGFR)( C225 )
Catalog No. M21142 CAS No. 205923-56-4
Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 260 | In Stock |
|
| 5MG | 434 | In Stock |
|
| 10MG | 627 | In Stock |
|
| 25MG | 981 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCetuximab (anti-EGFR)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
In Vitro——
-
In Vivo——
-
SynonymsC225
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Areacancer
-
IndicationColorectal Cancer
Chemical Information
-
CAS Number205923-56-4
-
Formula Weight2756.23
-
Molecular FormulaC107H179N35O36S7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huang S M Bock J M Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation Apoptosis and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res 1999 59(8):1935-1940.
molnova catalog
related products
-
JCN037
JCN037 is potent, non-covalent and brain-penetrant inhibitor of EGFR(EGFR, p-wtEGFR and pEGFRvⅢ with IC50 of 2.49 nM, 3.95 nM, 4.48 nM , respectively).
-
PD 089828
PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM)
-
AZ7550
AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
Cart
sales@molnova.com